NCT00132951View on ClinicalTrials.gov

KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections

PHASE4TerminatedINTERVENTIONAL
Enrollment

2,051

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Respiratory Tract InfectionsChronic BronchitisPneumonia
Interventions
DRUG

Telithromycin

Telithromycin (AECB: 2 tablets per day for Days 1-5; CAP: 2 tablets per day for Days 1-7)

DRUG

Azithromycin

Azithromycin (AECB: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5; CAP: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5 then 2 placebo tablets per day for Days 6-7)

Trial Locations (2)

Unknown

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Québec

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00132951 - KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections | Biotech Hunter | Biotech Hunter